Adaptimmune Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	178.03	60.28	27.15	6.15	3.96	Upgrade
Revenue Growth (YoY)	195.34%	122.05%	341.50%	55.36%	252.76%	Upgrade
Cost of Revenue	149.13	126.51	127.73	111.09	91.57	Upgrade
Gross Profit	28.9	-66.23	-100.58	-104.94	-87.61	Upgrade
Selling, General & Admin	81.31	64.46	63.39	57.31	45.8	Upgrade
Operating Expenses	81.31	64.46	63.39	57.31	45.8	Upgrade
Operating Income	-52.41	-130.69	-163.97	-162.25	-133.41	Upgrade
Interest Expense	-3.35	-	-	-	-	Upgrade
Interest & Investment Income	6.6	5.96	1.54	1.1	2.31	Upgrade
Currency Exchange Gain (Loss)	-1.73	-0.81	-0.54	3.85	1.11	Upgrade
Other Non Operating Income (Expenses)	-	-	-	-0.01	-0.03	Upgrade
EBT Excluding Unusual Items	-50.89	-125.54	-162.96	-157.31	-130.02	Upgrade
Merger & Restructuring Charges	-5.95	-9.05	-	-	-	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	0.01	0.09	Upgrade
Asset Writedown	-10.4	-	-	-	-	Upgrade
Other Unusual Items	-	22.05	-	-	-	Upgrade
Pretax Income	-67.24	-112.54	-162.96	-157.3	-129.93	Upgrade
Income Tax Expense	3.58	1.34	2.5	0.79	0.16	Upgrade
Net Income	-70.81	-113.87	-165.46	-158.09	-130.09	Upgrade
Net Income to Common	-70.81	-113.87	-165.46	-158.09	-130.09	Upgrade
Shares Outstanding (Basic)	252	201	161	156	142	Upgrade
Shares Outstanding (Diluted)	252	201	161	156	142	Upgrade
Shares Change (YoY)	25.48%	24.73%	3.47%	9.37%	35.72%	Upgrade
EPS (Basic)	-0.28	-0.57	-1.03	-1.01	-0.91	Upgrade
EPS (Diluted)	-0.30	-0.57	-1.03	-1.02	-0.91	Upgrade
Free Cash Flow	-74.09	-145.56	-171.27	2.16	-55.93	Upgrade
Free Cash Flow Per Share	-0.29	-0.72	-1.06	0.01	-0.39	Upgrade
Gross Margin	16.23%	-109.86%	-	-	-	Upgrade
Operating Margin	-29.44%	-216.81%	-603.97%	-2638.58%	-3370.52%	Upgrade
Profit Margin	-39.78%	-188.90%	-609.46%	-2570.99%	-3286.81%	Upgrade
Free Cash Flow Margin	-41.62%	-241.47%	-630.86%	35.05%	-1413.14%	Upgrade
EBITDA	-41.18	-120.85	-157.89	-155.68	-125.81	Upgrade
EBITDA Margin	-23.13%	-200.48%	-	-	-	Upgrade
D&A For EBITDA	11.23	9.84	6.08	6.57	7.59	Upgrade
EBIT	-52.41	-130.69	-163.97	-162.25	-133.41	Upgrade
EBIT Margin	-29.44%	-216.81%	-	-	-	Upgrade
Revenue as Reported	178.03	60.28	27.15	6.15	3.96	Upgrade

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q